Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China's Class 1 pathway for innovative drugs.

Monica Joanna Elnekaveh's advocacy began when Eleanor was initially diagnosed with two mosaic gaba receptor gene deletions (GABRA1 and GABRG2). Driven by the urgent need for treatments, Monica founded ...

Under this partnership, Grann will lead proof-of-concept and preclinical animal studies targeting GABAAR variants, applying the same innovative therapeutic platform and scientific rigor that made the ...

Damona Pharmaceuticals Inc. has obtained IND clearance from the FDA for DPX-101 for the treatment of cognitive deficits in brain disorders, including major depressive disorder. The company plans to ...

SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China's ...